Genomatica Clears Way for ‘Sustainable Chemical’ Demo Plant

San Diego’s Genomatica says it has checked off another technical accomplishment in its quest to take the “petroleum” out of the petrochemical industry.

After showing last year that it had engineered bacteria to make butanediol, a key industrial chemical also known as BDO, Genomatica says it now can make BDO in commercial grade batches. In an announcement today, Genomatica says its latest technical feat clears the way for construction of a small-scale industrial demonstration facility. The startup got $20 million in venture funding two years ago from Silicon Valley’s Mohr Davidow Ventures, Draper Fisher Jurvetson, and Alloy Ventures, so Genomatica may require another venture round before it embarks on construction.

Christophe Schilling
Christophe Schilling

“The recent achievement allows us to know that every step in our process works” and “fully validates” the technology, Genomatica’s Christophe Schilling told me last week. He estimates that construction of a BDO demonstration plant could begin early next year and would cost between $10 million and $15 million. Schilling, who co-founded the company in 2000, was named as Genomatica’s CEO last month, replacing former CEO Chris Gann.

Like most hydrocarbon products, BDO is currently produced from crude oil under tremendous heat and pressure in oil refinery “cracking” units. So Genomatica’s approach represents a potential revolution for the chemical industry, one that would replace an industrial process based on fossil fuel with a biotech-based process that uses sustainable technology.

Another amazing factoid in this is that BDO is normally toxic to E coli. Yet Genomatica has engineered the bacteria’s genes to churn out BDO while consuming sugar, oxygen, and other nutrients in fermentation tanks.

The global petrochemical industry makes about 3 billion pounds of BDO a year for a worldwide market estimated at almost $3 trillion a year.

The colorless, viscous liquid is what Schilling calls an “intermediate chemical.” As I reported in October, the pharmaceutical industry uses BDO to make

Author: Bruce V. Bigelow

In Memoriam: Our dear friend Bruce V. Bigelow passed away on June 29, 2018. He was the editor of Xconomy San Diego from 2008 to 2018. Read more about his life and work here. Bruce Bigelow joined Xconomy from the business desk of the San Diego Union-Tribune. He was a member of the team of reporters who were awarded the 2006 Pulitzer Prize in National Reporting for uncovering bribes paid to San Diego Republican Rep. Randy “Duke” Cunningham in exchange for special legislation earmarks. He also shared a 2006 award for enterprise reporting from the Society of Business Editors and Writers for “In Harm’s Way,” an article about the extraordinary casualty rate among employees working in Iraq for San Diego’s Titan Corp. He has written extensively about the 2002 corporate accounting scandal at software goliath Peregrine Systems. He also was a Gerald Loeb Award finalist and National Headline Award winner for “The Toymaker,” a 14-part chronicle of a San Diego start-up company. He takes special satisfaction, though, that the series was included in the library for nonfiction narrative journalism at the Nieman Foundation for Journalism at Harvard University. Bigelow graduated from U.C. Berkeley in 1977 with a degree in English Literature and from the Columbia University Graduate School of Journalism in 1979. Before joining the Union-Tribune in 1990, he worked for the Associated Press in Los Angeles and The Kansas City Times.